Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
BioCardia signs $500,000 deal with Japanese biotechnology company » 08:26
04/26/21
04/26
08:26
04/26/21
08:26
BCDA

BioCardia

$3.80 /

+0.08 (+2.15%)

BioCardia announced that…

BioCardia announced that it has entered into an agreement with a leading Japanese biotechnology company related to BioCardia Helix catheter biotherapeutic delivery product candidates. Under the terms of the agreement, BioCardia will receive $500,000, a portion of which is creditable for biotherapeutic delivery products and support services. The agreement has a one-year term with an option to negotiate for a non-exclusive world-wide license to BioCardia Helix catheter biotherapeutic delivery product candidates for certain cell types for cardiac indications.

ShowHide Related Items >><<
BCDA BioCardia
$3.80 /

+0.08 (+2.15%)

BCDA BioCardia
$3.80 /

+0.08 (+2.15%)

04/16/21 Dawson James
Dawson James downgrades BioCardia, sees capital raise this year
04/16/21 Dawson James
BioCardia downgraded to Neutral from Buy at Dawson James
09/21/20
Fly Intel: Top five analyst initiations
09/21/20 Alliance Global Partners
BioCardia initiated with a Buy at Alliance Global Partners
BCDA BioCardia
$3.80 /

+0.08 (+2.15%)

BCDA BioCardia
$3.80 /

+0.08 (+2.15%)

Conference/Events
BioCardia participates in a conference call with Maxim » 04:55
04/21/21
04/21
04:55
04/21/21
04:55
BCDA

BioCardia

$3.49 /

-0.15 (-4.12%)

Biotechnology Analyst…

Biotechnology Analyst McCarthy holds a conference call with CEO Altman & CFO McClung on April 21.

ShowHide Related Items >><<
BCDA BioCardia
$3.49 /

-0.15 (-4.12%)

BCDA BioCardia
$3.49 /

-0.15 (-4.12%)

04/16/21 Dawson James
Dawson James downgrades BioCardia, sees capital raise this year
04/16/21 Dawson James
BioCardia downgraded to Neutral from Buy at Dawson James
09/21/20
Fly Intel: Top five analyst initiations
09/21/20 Alliance Global Partners
BioCardia initiated with a Buy at Alliance Global Partners
BCDA BioCardia
$3.49 /

-0.15 (-4.12%)

BCDA BioCardia
$3.49 /

-0.15 (-4.12%)

Downgrade
Dawson James downgrades BioCardia, sees capital raise this year » 06:40
04/16/21
04/16
06:40
04/16/21
06:40
BCDA

BioCardia

$4.11 /

+0.05 (+1.23%)

Dawson James analyst…

Dawson James analyst Jason Kolbert downgraded BioCardia to Neutral from Buy without a price target. The analyst expects the company to be back in the capital markets raising again, later this year. Higher dilution from another capital raise impacts the valuation, Kolbert tells investors in a research note.

ShowHide Related Items >><<
BCDA BioCardia
$4.11 /

+0.05 (+1.23%)

BCDA BioCardia
$4.11 /

+0.05 (+1.23%)

04/16/21 Dawson James
BioCardia downgraded to Neutral from Buy at Dawson James
09/21/20
Fly Intel: Top five analyst initiations
09/21/20 Alliance Global Partners
BioCardia initiated with a Buy at Alliance Global Partners
BCDA BioCardia
$4.11 /

+0.05 (+1.23%)

BCDA BioCardia
$4.11 /

+0.05 (+1.23%)

Downgrade
BioCardia downgraded to Neutral from Buy at Dawson James » 06:20
04/16/21
04/16
06:20
04/16/21
06:20
BCDA

BioCardia

$4.11 /

+0.05 (+1.23%)

Dawson James analyst…

Dawson James analyst Jason Kolbert downgraded BioCardia to Neutral from Buy.

ShowHide Related Items >><<
BCDA BioCardia
$4.11 /

+0.05 (+1.23%)

BCDA BioCardia
$4.11 /

+0.05 (+1.23%)

09/21/20
Fly Intel: Top five analyst initiations
09/21/20 Alliance Global Partners
BioCardia initiated with a Buy at Alliance Global Partners
BCDA BioCardia
$4.11 /

+0.05 (+1.23%)

BCDA BioCardia
$4.11 /

+0.05 (+1.23%)

Conference/Events
BioCardia participates in a conference call with Maxim » 11:28
04/14/21
04/14
11:28
04/14/21
11:28
BCDA

BioCardia

$4.25 /

+0.01 (+0.24%)

Biotechnology Analyst…

Biotechnology Analyst McCarthy holds a conference call with CEO Altman & CFO McClung on April 21.

ShowHide Related Items >><<
BCDA BioCardia
$4.25 /

+0.01 (+0.24%)

BCDA BioCardia
$4.25 /

+0.01 (+0.24%)

09/21/20
Fly Intel: Top five analyst initiations
09/21/20 Alliance Global Partners
BioCardia initiated with a Buy at Alliance Global Partners
BCDA BioCardia
$4.25 /

+0.01 (+0.24%)

BCDA BioCardia
$4.25 /

+0.01 (+0.24%)

Over a month ago
Hot Stocks
BioCardia announces anticipated upcoming milestones » 08:12
03/30/21
03/30
08:12
03/30/21
08:12
BCDA

BioCardia

$4.00 /

-0.14 (-3.38%)

Anticipated Upcoming…

Anticipated Upcoming Milestones: Q2 2021: Phase III pivotal trial prespecified independent DSMB Review of CardiAMP Heart Failure trial; Q2 2021: Phase III pivotal trial first patient enrolled in CardiAMP Chronic Myocardial Ischemia Trial. Other 2021 anticipated milestones include: Roll in cohort safety data from BCDA-02, our CardiAMP autologous cell therapy under Phase III development for the treatment of chronic myocardial ischemia. Investigational New Drug acceptance of Phase I/II program of BCDA-03, our allogeneic Neurokinin-1 receptor positive Mesenchymal Stem Cells for the treatment of ischemic heart failure intended initially for those patients excluded from BCDA-01. IND acceptance of Phase I/II program for BCDA-04, our allogeneic NK1R+ MSC Phase I/II program for the treatment of acute respiratory distress resulting from COVID-19.

ShowHide Related Items >><<
BCDA BioCardia
$4.00 /

-0.14 (-3.38%)

BCDA BioCardia
$4.00 /

-0.14 (-3.38%)

09/21/20
Fly Intel: Top five analyst initiations
09/21/20 Alliance Global Partners
BioCardia initiated with a Buy at Alliance Global Partners
BCDA BioCardia
$4.00 /

-0.14 (-3.38%)

BCDA BioCardia
$4.00 /

-0.14 (-3.38%)

Earnings
BioCardia reports 2020 EPS ($1.48), consensus ($1.57) » 08:11
03/30/21
03/30
08:11
03/30/21
08:11
BCDA

BioCardia

$4.00 /

-0.14 (-3.38%)

Reports 2020 revenue…

Reports 2020 revenue $145,000, consensus $270,000. "We continue to recognize and thank our many outstanding clinical partners and their teams who are on the front lines of dealing with the COVID-19 situation nationwide as we work with them to accelerate our pivotal cell therapy clinical trials," said BioCardia CEO Peter Altman, Ph.D. "We also recognize the proactive efforts of the FDA to provide guidelines to help protect patients and preserve the integrity of ongoing clinical trials. The ongoing dedication to patient care, even at the potential risk to healthcare workers' own health, is a testament to the commitment we have seen ourselves in their work on our clinical programs."

ShowHide Related Items >><<
BCDA BioCardia
$4.00 /

-0.14 (-3.38%)

BCDA BioCardia
$4.00 /

-0.14 (-3.38%)

09/21/20
Fly Intel: Top five analyst initiations
09/21/20 Alliance Global Partners
BioCardia initiated with a Buy at Alliance Global Partners
BCDA BioCardia
$4.00 /

-0.14 (-3.38%)

BCDA BioCardia
$4.00 /

-0.14 (-3.38%)

Hot Stocks
BioCardia signs agreement with Japanese pharmaceutical company » 08:12
02/23/21
02/23
08:12
02/23/21
08:12
BCDA

BioCardia

$4.16 /

-0.21 (-4.81%)

BioCardia announced that…

BioCardia announced that it has entered into an agreement with a leading Japanese pharmaceutical company related to BioCardia Helix catheter biotherapeutic delivery product candidates. Under the terms of the agreement, BioCardia will receive a $500,000 up-front payment, a portion of which is creditable for biotherapeutic delivery products and support services. The agreement has a one-year term with an option to negotiate for a non-exclusive world-wide license to BioCardia Helix catheter biotherapeutic delivery product candidates for certain cell types for cardiac indications. "Our collaboration with this leading Japanese pharmaceutical company further validates our core Helix biotherapeutic delivery technology as the leading delivery platform for local cell, gene and protein-based therapy to the heart. To our knowledge, the Helix system is currently the only intra-myocardial delivery system in clinical use worldwide. We are grateful for the additional recognition of the Helix system's potential to enable the successful development of others' therapies," said BioCardia CEO Peter Altman, Ph.D. "Recent publications have demonstrated our Helix delivery platform is the most efficient, and has the best clinical performance. These Helix system advantages are believed to underlie our recently reported CardiAMP(TM) cell therapy clinical results in heart failure. We look forward to bringing all of our experience and delivery technologies to bear to help advance this partner's important therapeutic development efforts."

ShowHide Related Items >><<
BCDA BioCardia
$4.16 /

-0.21 (-4.81%)

BCDA BioCardia
$4.16 /

-0.21 (-4.81%)

09/21/20
Fly Intel: Top five analyst initiations
09/21/20 Alliance Global Partners
BioCardia initiated with a Buy at Alliance Global Partners
BCDA BioCardia
$4.16 /

-0.21 (-4.81%)

BCDA BioCardia
$4.16 /

-0.21 (-4.81%)

Hot Stocks
BioCardia appoints Sujith Shetty as CMO » 08:42
02/17/21
02/17
08:42
02/17/21
08:42
BCDA

BioCardia

$4.97 /

-0.13 (-2.55%)

BioCardia announced…

BioCardia announced clinical leadership changes. Dr. Sujith Shetty who has been with the Company for almost two years in the capacity of Vice President of Clinical and Regulatory will assume the role of CMO, replacing Dr. Eric Duckers, who resigned as CMO of the Company to pursue other opportunities, effective as of February 15th, 2021. Simultaneous with his resignation, Dr. Duckers entered into a consulting agreement to continue to provide support for the ongoing CardiAMP Heart Failure Trial and its leadership team. Ms. Debby Holmes-Higgin who has been with the Company for more than three years will continue to serve as Vice President of Clinical with expanded responsibilities. Both Dr. Shetty and Ms. Holmes-Higgin will be supported by Dr. Hans-Peter Stoll, who recently assumed the role of consulting Medical Monitor for the CardiAMP clinical study.

ShowHide Related Items >><<
BCDA BioCardia
$4.97 /

-0.13 (-2.55%)

BCDA BioCardia
$4.97 /

-0.13 (-2.55%)

09/21/20
Fly Intel: Top five analyst initiations
09/21/20 Alliance Global Partners
BioCardia initiated with a Buy at Alliance Global Partners
BCDA BioCardia
$4.97 /

-0.13 (-2.55%)

BCDA BioCardia
$4.97 /

-0.13 (-2.55%)

Options
Five new option listings and two option delistings on February 9th » 08:30
02/09/21
02/09
08:30
02/09/21
08:30
BCDA

BioCardia

$5.19 /

+0.49 (+10.43%)

, GMTX

Gemini Therapeutics

$11.87 /

-0.65 (-5.19%)

, GNLN

Greenlane

$5.97 /

+0.42 (+7.57%)

, PAX

Patria Investments

$22.76 /

+0.8 (+3.64%)

, PRPH

ProPhase Labs

$10.74 /

+0.29 (+2.78%)

, CLCT

Collectors Universe

$91.92 /

+ (+0.00%)

, FSDC

FS Development

$12.64 /

-0.02 (-0.16%)

New option listings for…

New option listings for February 9th include BioCardia Inc (BCDA), Gemini Therapeutics Inc (GMTX), Greenlane Holdings (GNLN), Patria Investments Ltd (Class A Stock) (PAX), and ProPhase Labs (PRPH). Option delistings effective February 9th include Collectors Universe Inc (CLCT) and FS Development Corporation (Class A Stock) (FSDC).

ShowHide Related Items >><<
PRPH ProPhase Labs
$10.74 /

+0.29 (+2.78%)

GNLN Greenlane
$5.97 /

+0.42 (+7.57%)

GMTX Gemini Therapeutics
$11.87 /

-0.65 (-5.19%)

CLCT Collectors Universe
$91.92 /

+ (+0.00%)

BCDA BioCardia
$5.19 /

+0.49 (+10.43%)

BCDA BioCardia
$5.19 /

+0.49 (+10.43%)

09/21/20
Fly Intel: Top five analyst initiations
09/21/20 Alliance Global Partners
BioCardia initiated with a Buy at Alliance Global Partners
GMTX Gemini Therapeutics
$11.87 /

-0.65 (-5.19%)

GNLN Greenlane
$5.97 /

+0.42 (+7.57%)

03/31/20 Roth Capital
Greenlane price target lowered to $4 from $9 at Roth Capital
PAX Patria Investments
$22.76 /

+0.8 (+3.64%)

PRPH ProPhase Labs
$10.74 /

+0.29 (+2.78%)

01/20/21 Dawson James
ProPhase Labs initiated with a Buy at Dawson James
CLCT Collectors Universe
$91.92 /

+ (+0.00%)

FSDC FS Development
$12.64 /

-0.02 (-0.16%)

PRPH ProPhase Labs
$10.74 /

+0.29 (+2.78%)

CLCT Collectors Universe
$91.92 /

+ (+0.00%)

BCDA BioCardia
$5.19 /

+0.49 (+10.43%)

  • 22
    Jan
CLCT Collectors Universe
$91.92 /

+ (+0.00%)

PRPH ProPhase Labs
$10.74 /

+0.29 (+2.78%)

PAX Patria Investments
$22.76 /

+0.8 (+3.64%)

GNLN Greenlane
$5.97 /

+0.42 (+7.57%)

CLCT Collectors Universe
$91.92 /

+ (+0.00%)

FSDC FS Development
$12.64 /

-0.02 (-0.16%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.